0.4925

3.82% 0.0181

Cognition Therapeutics Inc (CGTX)

Overview News Price History Financials Discussions Forecast

Cognition Therapeutics Inc stock is traded at $0.4925, with a volume of 289.56K. It is up +3.82% in the last 24 hours and up +13.22% over the past month. Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Previous Close:

$0.4744

Open:

$0.4745

24h Volume:

289.56K

Relative Volume:

0.51

Market Cap:

$19.67M

Revenue:

Net Income/Loss:

$-22.83M

P/E Ratio:

-0.5727

EPS:

-0.86

Net Cash Flow:

$-20.87M

1W Performance:

-13.60%

1M Performance:

+13.22%

6M Performance:

-74.48%

1Y Performance:

-53.54%

1-Day Range:

$0.4712

$0.51

1-Week Range:

$0.4367

$0.5775

52-Week Range:

$0.34

$2.95

Cognition Therapeutics Inc Stock (CGTX) Company Profile

Name

Cognition Therapeutics Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

412-481-2210

Address

2403 SIDNEY STREET, PITTSBURGH

Employee

Twitter

Next Earnings Date

2024-08-08

Latest SEC Filings

CGTX's Discussions on Twitter

Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-03-21	Initiated	B. Riley Securities	Buy
Nov-03-21	Initiated	Oppenheimer	Outperform

Cognition Therapeutics Inc Stock (CGTX) Latest News

Nov 04, 2024

Cognition Therapeutics stock rated Buy, target held amid CT1812 data By Investing.com - Investing.com UK

Nov 04, 2024

November’s Small-Cap Treasures: 3 Stocks Poised for Growth - MarketBeat

Nov 04, 2024

Cognition Therapeutics (NASDAQ:CGTX) Earns Buy Rating from Chardan Capital - Defense World

Nov 04, 2024

Oct 31, 2024

Cognition Therapeutics Presents Poster of Participant - GlobeNewswire

Oct 31, 2024

Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with - The Bakersfield Californian

Oct 31, 2024

Oct 29, 2024

Cognition Therapeutics reports potential Alzheimer's treatment breakthrough By Investing.com - Investing.com South Africa

Oct 29, 2024

Cognition Therapeutics reports potential Alzheimer's treatment breakthrough - Investing.com

Oct 29, 2024

Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD - GlobeNewswire

Oct 29, 2024

Cognition Therapeutics (CGTX) Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD - StreetInsider.com

Oct 29, 2024

Oct 28, 2024

Dementia Associated With Alzheimer’s Disease Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail

Oct 28, 2024

Dementia Associated With Alzheimer's Disease Pipeline - openPR

Oct 28, 2024

Oct 23, 2024

Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of - GlobeNewswire

Oct 23, 2024

Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of CT1812 in Mild-to-Moderate ... - The Bakersfield Californian

Oct 23, 2024

Oct 22, 2024

Cognition Therapeutics Releases New Episode of - GlobeNewswire

Oct 22, 2024

Oct 14, 2024

Tau Inhibitors Clinical Trial Pipeline Analysis Demonstrates 25+ Key Companies At The Horizon Expected To Transform The Treatment Paradigm, Assesses D... - MENAFN.COM

Oct 14, 2024

Tau Inhibitors Clinical Trial Pipeline Analysis - GlobeNewswire

Oct 14, 2024

Tau Inhibitors Clinical Trial Pipeline Analysis Demonstrates 25+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - India Shorts

Oct 14, 2024

Oct 09, 2024